Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Genovis AB

Market Cap 1.21B 126M 110M 102M 95.5M 179M 11.92B 180M 469M 5.87B 474M 464M 20.37B P/E 2026 *
44.7x
P/E 2027 * 29.5x
Enterprise Value 1.09B 114M 99.54M 92.19M 86.3M 162M 10.77B 163M 424M 5.3B 429M 419M 18.41B EV / Sales 2026 *
7.34x
EV / Sales 2027 * 5.62x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
1 day-0.97%
1 week-6.44%
Current month-9.31%
1 month-8.63%
3 months+13.09%
6 months-10.63%
Current year-13.79%
1 week 18.32
Extreme 18.32
19.9
1 month 18.32
Extreme 18.32
21.1
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
29.8
3 years 15.64
Extreme 15.64
57.6
5 years 15.64
Extreme 15.64
90
10 years 1.28
Extreme 1.28
90
Manager TitleAgeSince
Chief Executive Officer 55 2015-05-04
Director of Finance/CFO 55 2021-12-31
Chief Tech/Sci/R&D Officer 42 2016-12-31
Director TitleAgeSince
Director/Board Member 77 2013-12-31
Director/Board Member 65 2018-12-31
Chairman 74 2020-05-04
Date Insider Type Main position Quantity % Market Cap.
05-14Buy 4,146 0.0063%
02-23Buy

Chief Financial Officer

2,470 0.0037%
02-23Buy

Chief Financial Officer

3,137 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-6.44%-33.14%-63.10% 126M
+2.07%+0.12%+168.17%+253.96% 17.47B
+2.15%+1.85%-42.64%-22.56% 9.33B
+0.65%-0.63%+31.15%+11.83% 6.76B
+3.42%+2.78%-32.22% - 5.22B
-1.64%-3.63%-27.65%-32.78% 4.88B
+10.00%+20.71%+105.80%+104.59% 4.54B
+8.17%+20.51%+221.51%-39.98% 4.41B
+2.07%-2.17%-31.05%-33.48% 3.95B
-1.74%-2.46%-17.42%-43.06% 2.57B
Average +2.42%+2.87%+34.25%+15.05% 5.93B
Weighted average by Cap. +2.62%+3.15%+63.00%+77.60%

Financials

2026 *2027 *
Net sales 149M 15.55M 13.56M 12.56M 11.75M 22.05M 1.47B 22.18M 57.73M 722M 58.37M 57.12M 2.51B 187M 19.53M 17.03M 15.77M 14.76M 27.69M 1.84B 27.86M 72.51M 907M 73.31M 71.74M 3.15B
Net income 24.05M 2.51M 2.19M 2.03M 1.9M 3.56M 237M 3.58M 9.32M 117M 9.42M 9.22M 405M 38.35M 4M 3.49M 3.23M 3.03M 5.68M 378M 5.71M 14.86M 186M 15.03M 14.7M 646M
Net Debt -117M -12.18M -10.62M -9.83M -9.2M -17.26M -1.15B -17.37M -45.21M -566M -45.71M -44.73M -1.96B -159M -16.6M -14.47M -13.4M -12.55M -23.53M -1.57B -23.67M -61.62M -771M -62.3M -60.97M -2.68B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
36
Date Price Change Volume
26-06-18 18.32 kr -0.97% 26,426
26-06-17 18.50 kr -2.63% 34,033
26-06-16 19.00 kr -1.55% 38,539
26-06-15 19.30 kr -1.43% 26,663
26-06-12 19.58 kr -1.81% 21,784
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
18.32SEK
Average target price
32.67SEK
Spread / Average Target
+78.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!